Abstract

Background: Chronic myeloid leukemia (CML) is the commonest neoplasm associated with a recurrent chromosomal aberration (fused bcr-abl gene on the Philadelphia chromosome). The current used methods for generating bcr-abl gene are very expensive and not feasible in labs with limited facilities. So this study aimed at using a simple, safe and non expensive method for generating bcr-abl gene to be used in CML researches.

Methods: Bcr-abl expression was evaluated in two groups; umbilical cord blood CD34+ HSCs (UCB CD34+ HSCs) nucleofected with the P210pcDNA3 plasmid (n=5) and UCB CD34+ HSCs nucleofected with the GFP-encoding plasmid (pMAX-GFP) (n=5). Then, neomycin (G418) antibiotic selection was done. Stable bcr-abl gene expression in G418 resistant P210pcDNA3 UCB CD34+ HSCs clones, was evaluated through quantitative PCR analysis of the expression of interleukin one receptor accessory protein (IL1RAP) gene. IL1RAP gene is newly discovered to be expressed on the surface of bcr-abl positive cells.

Results: G418 resistant P210pcDNA3 clones showed up to eleven-fold increase in IL1RAP gene expression compared to pMAX-GFP clones. Our results demonstrated how nucleofection of conventional plasmids is likely to induce gene expression in HSCs.

Conclusion: This simple method of generating bcr-abl gene expressing CD34+ HSCs, shall open new revenues for chronic myeloid leukemia research especially in laboratories, not equipped for advanced and expensive cancer research. Furthermore IL1RAP over expression on the surface of bcr-abl +CD34+ HSCs, could be used as indicator for successful stable bcr-abl expression.

Keywords: Chronic myeloid leukemia; Nucleofection; IL1RAP Gene; P210pcDNA3

Abbreviations: HSCs: Hematopoietic Stem Cells; UCB CD34+ HSCs: Umbilical Cord Blood Hematopoietic Stem Cells Positive for Cluster of Differentiation 34; CMV: Cytomegalovirus; Bcr-abl: Break Point Cluster Reigon-Abelson murine leukemia viral oncogene homolog 1; (P210): Protein210; CML: Chronic Myeloid Leukemia; IL1RAP: Interleukin One Receptor Accessory Protein; GFP: Green Fluorescence Protein; G418: Geneticin 418 Aminoglycoside Antibiotic; cDNA: complementary DNA; CMV: Cytomegalovirus; NeoR: Neomycin Resistance gene

Introduction

The biological properties of hematopoietic stem cells (HSCs) and their accessibility for ex vivo manipulation, render them one of the most promising targets of non viral gene modification approaches [1]. They represent the stem cell population where hallmark genetic aberrations of hematological disorders originate; the commonest of which is chronic myeloid leukemia (CML). Chronic myeloid leukemia (CML) is a myeloproliferative disorder of pluripotent hematopoietic stem cells (CD34+), affecting one or all cell lines (erythroid, platelet and myeloid). CML is characterized by a recurrent chromosomal aberration; the Philadelphia chromosome which carries the fused bcr-abl gene which has multiple isoforms with P210 being the commonest [2].

In the last few years, the advent of CML research has opened a new era in studying the disease pathogenesis and treatment modalities. However, resource limitations in many centers may hinder the establishment of valid study methods. Such centers’ challenge is to tailor simple, non expensive, and accurate techniques that give high quality results. It was reported that simple in vitro CML models are preferred to the in vivo mouse models where CML stem cells showed poor or no engraftment in immune deficient mice [2]. Many researchers tried to generate CML stem cell models through retroviral transduction of umbilical cord blood CD34+ hematopoietic stem cells (UCB CD34+ HSCs) to induce full length P210bcr-abl expression [2-4]. Although highly efficient gene transfer and long-term expression can be achieved with viral vectors, serious safety risks such as tumorigenicity have been identified due to insertional mutagenesis and uncontrolled gene expressions [5,6].

Despite being the most studied prototypic hematopoietic neoplasm, no plasmid-based approaches were used to generate ex vivo models of CML cancer stem cells. For maintaining an ex vivo model of HSCs disorders, the ideal vector should reside into the nucleus of repopulating cells and should ensure expression of the trans gene for the entire lifespan of the cell and its progeny [1]. That is why many new research studies focused on developing episomal self-replicating plasmid-based systems for their efficiency in maintaining gene expression for multiple generations without integration in the host cell genome [7-9]. However,
constructing such vectors could be laborious and needs a state-of-the-art devices which couldn't be available in limited facilities.

Few reports are available about using conventional expression plasmids for stem cell reprogramming specially for the induction of the expression of full length bcr-abl gene through transfection CD34+HSCs [10]. Even, these few reports used either a cell line (cos cell line) rather than primary culture [11] or a complicated promoter type (tet responsive) rather than a constitutional one [12].

In 2010, a group of scientists identified up regulation of a new surface biomarker on bcr-abl expressing cells: interleukin one receptor associated protein (IL1RAP). This discovery offers new options for CML stem cells identification [1]. IL1RAP was suggested to be regulated by the well-known signaling cascade, activated by bcr-abl fused gene [13]. To this end we tried to generate a simple in vitro model of CML like stem cells using a conventional expression plasmid; the P210pcDNA3 plasmid which carries the full length bcr-abl fused gene. Our aim was mainly to detect the efficiency of nucleofection of a simple constitutional expression vector in inducing stable gene expression and to assess this efficiency using the least number of advanced techniques.

**Methods**

We tailored a method to ensure the delivery of the bcr-abl gene into the nucleus using a simple conventional mammalian expression vector. Umbilical cord blood CD34+ hematopoietic stem cells (UCBCD34+HSCs) were nucleofected with the P210pcDNA3 plasmid to induce bcr-abl expression in the CD34+ HSCs. P210pcDNA3 plasmid, is a commercial conventional plasmid that encodes the full length bcr-abl gene (P210), the hallmark of the CML disorder. This plasmid is characterized by its Cytomegalovirus virus (CMV) promoter for high-level expression in mammalian cell lines in addition to the neomycin-resistant cassette (Neo) for antibiotic selection of stably transfected eukaryotic cells [14]. Bcr-abl expression in the UCBCD34+HSCs was evaluated through real time PCR analysis of G418 resistant P210pcDNA3 clones for IL1RAP gene.

**P210pcDNA3 plasmid harvesting and verification**

P210 pcDNA3 Addgene plasmid # 27481, USA was harvested according to the manufacturer’s protocol after signing a material transfer agreement; MTA (Supplementary data). Then the plasmid was purified using the Plasmid Mini Kit (Qiagen, USA), then verified by gel electrophoresis.

**Nucleofection of cord blood-derived CD34+ cells**

UCB was obtained from Obstetrics and Gynaecology Department at Faculty of Medicine, Suez Canal University, Ismailia, Egypt and an informed consent obtained in accordance. After Ficoll-Hypaque (Mediatech Cellgro, German) gradient separation, UCB mononuclear cells were collected and enriched for CD34+ cells using Miltenyi MACS separation techniques (MiltenyiBiotec, USA). CD34+ cells were enriched to more than 93% purity, CD34+ cells were washed with 1-phosphate buffered saline/0.5% bovine serum albumin (Sigma-Aldrich, Germany). CD34+ were analyzed morphologically using the phase contrast inverted microscope and were identified as small lymphocyte-like cells that lack cytoplasmic granules and have prominent nucleoli [15]. Then, cells were resuspended at 0.5 to 1 × 10^6 cells/mL. 1 μL human CD34 cell Nucleofector solution (Amaxa Human CD34+ Cell Nucleofector Kit, Amaxa Biosystems, USA). First group of cells were nucleofected with 1 – 5 μg of bcr-abl expressing P210pcDNA3 plasmid while the second group of cells was nucleofected with 2 μg of the empty pMAX-GFP plasmids as indicated using program U-08 on the Nucleofector (Amaxa Biosystems, USA) device. Nucleofected cells were immediately transferred to 12-well plates containing 37°C pre warmed medium (RPMI 1640 10% fetal calf serum (FCS), 100 μg/ml streptomycin, 2 mM Ultra Glutamine, (Lonza Bioproducts, USA) and cells were incubated in humidified 37°C/5% CO2 incubator for 48 hours. A third group was left un nucleofected.

**Serial dilutions of the nucleofected CD34+ cells**

Post nucleofection confluent CD34+ cells, obtained 48 hours of culture were serially diluted in a 24 well plate till reaching a cell count of 4000-5000 cells in order to use it as a starting cell count for G418 antibiotic selection. 400 μl of media were added to each well of a 24 well plate. Next, 100 μl of a 5 × 10^6 cells/ml solution were added to the first well and pipetted to mix. This well had the maximum number of cells. Next, 100 μl from the first well were taken and added to the next well, and mixed. The process was repeated. Then 100 μl were taken from the last well, which contained the minimum number of cells, then discarded.

**G418 selection of resistant clones**

Serially diluted UCB CD34+ HSCs were subjected to G418 selection using standard protocols [16]. Then each resistant clone was subcultured in a 24 well plate and was allowed to grow in a G418 selective medium, till suitable cell count was obtained (not more than 10^6 cells).

**IL1RAP gene expression analysis**

screening for successful bcr-abl gene stable expression was assessed. We didn't assess bcr-abl gene expression in the nucleofected cells, however, we assessed the expression of IL1RAP gene, a gene newly identified to be up regulated in bcr-abl expressing cells. Real-time PCR analysis was performed to cells nucleofected with the P210pcDNA3 plasmid and those nucleofected with the pMAX-GFP plasmid, both 48 hours and 14 days post nucleofection, using an ABI Prism 7500 analyzer (Applied Bio systems, USA) and Step One Plus (Applied Bio systems, USA) following manufacturer's protocols. All samples were analyzed in duplicates. Primers and probes for IL1RAP were obtained from Invitro, USA as assay-on demand primers. The relative quantity was calculated based on the ΔΔCt method [17] and normalized to GAPDH (Supplementary Figures S1-S9, Supplementary Tables S1and S6).

**Statistical analysis**

The mean, median and range of IL1RAP and GAPDH Ct values of test and control samples were tested for significance using the Mann-Whitney Test (Supplementary Tables S2). Expression levels are given as fold of expression considering the control sample equals one. The expression levels were tested for significance using Wilcoxon Signed-Ranks test [18]. The level of significance was set to p<0.05 (Supplementary Tables S3,S4,S5).

**Results**

**P210pcdna3 Plasmid Harvesting and Verification Results**

The presence of the desired bcr-abl gene fragment in the purified P210pcDNA3 plasmid (Figure 1A) was verified by gel electrophoresis after restriction enzyme digestion of the plasmid (Figure 1B). Two bands were visualized; the 7.2 Kb band referring to the bcr-abl gene fragment and the 5.4 Kb and referring to the pcDNA3 plasmid backbone.

**Nucleofection of cord blood-derived CD34+ cells results**

Cell confluence of both nucleofected and non-nucleofected cells (cultured for 48 hours) reached up to 90% (Figure 2C).
Resistant clones to G418 appear after two weeks of nucleofection

The resistant clone appeared at the well with the G418 concentration of 0.8mg/ml and cell concentration of 10^3 cells after two weeks from nucleofection. The resistant clone was sub cultured in another 96 well plate containing 0.8mg/ml in all wells and a single clone was observed in nearly every well.

IL1RAP over expression in cells nucleofected with P210pcDNA3 relative to those nucleofected with the empty vector Pmax-GFP

IL1RAP proved to be over expressed in cells nucleofected with P210pcDNA3 relative to those nucleofected with P210 pcDNA3 or those nucleofected with pMAX-GFP plasmid (an empty control vector). The expression levels after 48 hours ranged from two to nine folds change (Figure 2D and supplementary Table S4) while the expression levels in the subcultured G418 selected nucleofected cells ranged from four to eleven folds (Figure 2E).

Discussion

In this study, The P210 pcDNA3 plasmid was used for inserting the bcr-abl gene into the CD34+ hematopoietic stem cells. The PmaxGFP plasmid wasn’t used directly as a source of gene but used as a reporter plasmid because it has been previously tested by Hammer, who inserted the bcr-abl gene into two different cell types; the BAF3 and the Hela cells. The gene was successfully inserted into the Hela cells but failed in the BAF3 cell line[19].

Thus, Pmax GFP plasmid was used as a reporter plasmid only to avoid the risk of failure of the gene insertion into the CD34+ hematopoietic stem cells. However, the use of pcDNA3 plasmid as an expression vector, proved to be successful, in inducing the bcr-abl gene expression in our study. This was consistent with the results of another study [20] in which they used the same vector as an expression vector for encoding M2-tagged JNK1 wild-type and led to successful expression of the inserted gene. They used the G418 selection system at a concentration of 0.4–0.8 mg/ml that was similar to the concentration used in our study (0.75 mg/ml).

In the current study, nucleofection, the modified electroporation technique, was used for gene transfer in order to avoid the disadvantages of electroporation; cell damage and non specific transport of the intracellular components across cell membrane through the time of membrane electro premeability. Nucleofection uses a combination of electrical parameters, generated by a device called Nucleofector, with cell-type specific reagents to transfer a substrate directly into the cell nucleus (mainly extra-chromosomally, in case of circular DNA or intra-chromosomally, in case of linearized DNA), thus optimizing the electrical current intensity and length and increasing the specificity and proper targeting to the nucleus. Nucleofection preserves cell viability and intracellular systems are conserved [21]. In order to avoid the risk of improper gene integration and meticulous linearization [22], we didn’t use linearized DNA molecule (despite inducing stable gene expression) [23], we used circular DNA instead.

In this work IL1RAP gene over expression, in P210pcDNA3 nucleofected cells, was considered an indicator for stable bcr-abl gene expression according to Ren [13].

The difference between the fold change expression of IL1RAP gene in the nucleofected cells with bcr- abl gene after 48 h (up to 5 fold) and after 10 days (up to 11fold) in comparison with non nucleofected cells could be attributed to the timing of gene expression analysis. In this study, after forty eight hours, the DNA introduced in the transfection process didn’t integrate into the nuclear most probably due to DNA dilution through mitosis or degradation leading to weaker expression of the desired gene [24]. However, after selection by the G418 antibiotic, the IL1RAP gene expression was reassessed in the sub-cultured resistant clones containing the P210pcDNA3 plasmid. We found that the fold change of IL1RAP gene expression in the G418 selected cells,
was doubled (fold change: 11) relative to that of the non-G418 selected cells (fold change: 5). This selection guaranteed the assessment of only the cells expressing the IL1RAP gene and thus yielded high expression fold change.

Our results of over expression were close to but not identical to those reported by Jaras et al. where the retroviral P210 bcr-abl UCB CD34+ expressing cells (n:3) in their study showed higher expression level (up to 12 folds) compared to empty vector MIG control-expressing cells and normal bone marrow CD34+ stem cells which were not retrovirally transduced. This discrepancy could be attributed to the use of a different expression system in our study (expression plasmids; P210 pcDNA3) to induce the bcr-abl gene expression instead of the retroviruses used in their study. Stable gene expression characterized for retroviruses in comparison to transient expression achieved by plasmid vectors, is suggested to be responsible for such variation [25].

**Conclusion**

On overall, we conclude that, conventional plasmids could be used for studying Chronic Myeloid Leukemia especially in labs or research centers with limited resources. The nucleofection of a conventional plasmid is likely to induce stable gene expression in HSCs. Furthermore, bcr-abl mediated IL1RAP over expression on CML CD34+ HSCs, offers major target for CML anticancer drug development

**Acknowledgments**

We thank Professor Dr Yasser El-Wazir, physiology, for his technical help. We gratefully acknowledge, Addgene company for supplying us with the P210pcDNA3 plasmid “Addgene plasmid 27481”. Due thanks to Obstetrics and Gynaecology Department for supplying us with the Umbilical cord blood. Special thanks to Dr Nagla Hassan for supplying with the Amaxa® Human CD34+ Cell Nucleofector® Kit.

**References**

1. Papapetrou EP, Zoumbos NC, Athanassiadou A (2005) Genetic modification of hematopoietic stem cells with nonviral systems: past progress and future prospects. Gene Therapy 12: 118-130.
2. Jaras M, Johans P, Hansen N (2010) Isolation and killing of candidate chronic myeloid leukemia stem cells by antibody targeting of IL-1receptor accessory protein. PNAS 107: 16280-16285.
3. Zhao RC, Jiang Y, Verfaillie CM (2001) A model of human p210bcr/ABL-mediated chronic myelogenous leukemia by transduction of primary normal human CD34* cells with a BCR/ABL-containing retroviral vector. Blood 97: 2406-2412.
4. Saliesse S, Verfaillie CM (2003) BCR/ABL-mediated increased expression of multiple known and novel genes that may contribute to the pathogenesis of chronic myelogenous leukemia. Mol Cancer Ther 2: 173-182.
5. Park HJ, Yang F, Cho SW (2012) Nonviral delivery of genetic medicine for therapeutic angiogenesis. Advanced Drug Delivery Reviews 64: 40-52.
6. Thomas CE, Ehrhardt A, Kay MA (2003) Progress and problems with the use of...
viral vectors for gene therapy. Nature Reviews Genetics 4: 346-358.
7. Mack AA, Kroboth S, Rajesh D, Wang WB (2011) Generation of induced pluripotent stem cells from CD34+ cells across blood drawn from multiple donors with non-integrating epithelial vectors. PLoS One.
8. Meng X, Neises A, Su RJ, Payne KJ, Ritter L, et al (2012) Efficient Reprogramming of Human Cord Blood CD34+Cells Into Induced Pluripotent Stem Cells With OCT4 and SOX2 Alone. Molecular Therapy 20: 408-416.
9. Papapetrou EP, Ziros PG, Micheva ID, Zoumbos NC, Athanassiadou A (2006) Gene transfer into human hematopoietic progenitor cells with an episomal vector carrying an S/MAR element. Gene Therapy 13: 40-51.
10. Oka T, Sastry KJ, Nehete P, Schapiro SJ, Guo JQ, et al (1998) Evidence of specific immune response against P210 BCR-ABL in long term remission CML patients treated with interferon. Leukemia 12: 159-163.
11. Huang WR, Lu ZZ, Wang LS, Wang H, Duan HF, et al. (2007) Construction of 293p T2-P210 cell line enables expression of bcr/abl to be regulated by Tet-off inducing-expression-system. Journal of experimental Hematology 15: 224-228.
12. Auligi M, Fogli M, Curti A, Isidori A, Grupponi E, et al. (2006) Nucleofection is an efficient non viral transfection technique for human bone marrow-derived mesenchymal stem cells. Stem Cells 24: 454-461.
13. Ren R (2005) Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukemia. Nat Rev Cancer 5: 172-183.
14. Gorman Gorman C (1985) High efficiency gene transfer into mammalian cells. In DNA Cloning: A Practical Approach Volume II. Ed. D. M. Glover. Chapter (6): 143-190. IRL Press, Oxford.
15. Stella CC, Cazzola M, Fabritiis PD, Vincentitis AD, Gianni AM, et al. (1995) Cd34-Positive Cells: Biology And Clinical Relevance. Haematologica 80: 367-387.
16. Grimm S (2004) The art and design of genetic screens: mammalian culture cells. Nature Rev Gen S: 179-189.
17. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using realtime quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25: 402-408.
18. Goni R, García P, Foissac S (2009) The qPCR data statistical analysis. Integromics White Paper 1-9.
19. Hammer SG (2006) Cloning And Expression Of Wild-Type And Mutated Forms Of Bcr-Abl In A Mouse Pro-B Cell Line. Master Thesis In Pharmacy. Research Gate Department Of Pharmacology, Institute Of Pharmacy Faculty Of Medicine University Of Tromsø.
20. Goillot E, Raineaud J, Ranger A, Tepper RI, Davis RJ, et al. (1999) Mitogen-activated protein kinase-mediated Fas apoptotic signaling pathway. Proc Natl Acad Sci 94: 3302-3307.
21. Maasho K, Marusina A, Reynolds NM, Coligan JE, Borrego F (2004) Efficient gene transfer into the human natural killer cell line, NKL, using the amaxa nucleofection systemJournal of Immunological Methods 284: 133-140.
22. Groll A, Levin Y, Barbosa MC, Ravazzolo AP (2006) Linear DNA low efficiency transfection by liposome can be improved by the use of cationic lipid as charge neutralizer. Biotechnol Prog 22: 1220-1224.
23. Stuchbury G, Münch G (2010) Optimizing the generation of stable neuronal cell lines via pre-transfection restriction enzyme digestion of plasmid DNA. Cytotherapy 62: 189-194.
24. Durocher Y, Perret S, Kamen A (2002) High-level and high-throughput recombinant protein production by transient transfection of suspension-growing human 293-EBNA1 cells. Nucleic Acids Res.
25. Wilson C, Pearson RK, Belten HJ, O’Kane CJ, Grossniklaus U, et al. (1989) P-element-mediated enhancer detection: an efficient method for isolating and characterizing developmentally regulated genes Drosophila. Genes Dev 3: 1301-1313.